Fierce Pharma August 30, 2024
CDMO giant Catalent, which continues to wait on a twice-extended review by the Federal Trade Commission (FTC) of its sale to Novo Holdings for $16.5 billion, reported upbeat fourth-quarter earnings.
The company said it tallied net income of $23 million for its fiscal fourth quarter—which ran through the end of June—compared to a loss of $110 million for the same period a year ago. Catalent reported profit of 13 cents per share, with earnings adjusted for one-time gains and costs coming in at 65 cents per share, beating Wall Street analysts’ estimates of 46 cents per share.
Revenue for the quarter was $1.3 billion versus $1 billion a year ago. An average estimate from Zacks Investment Research had pegged expected...
Today's Sponsors
Today's Sponsor